HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors
Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Profiles of Intratumoral Injection of HP007 Injection as Monotherapy in Patients With Relapsed or Refractory Advanced Solid Tumors, and to Explore the Preliminary Efficacy of HP007
This study is an open-label, dose-escalation and expansion, Phase I clinical study to evaluate the safety, tolerability, PK characteristics and preliminary antitumor activity of HP007 monotherapy in patients with advanced malignant solid tumors.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Niannian Wang, Project Manager
- Telefonnummer: +86 13161547878
- E-mail: niannian_wang@junshipharma.com
Studiesteder
-
-
Jilin
-
Changchun, Jilin, Kina, 130000
- Rekruttering
- The First Hospital of Jilin University
-
Kontakt:
- Yanhua Ding, Chief Physician
- E-mail: dingyanh@jlu.edu.cn
-
Ledende efterforsker:
- Yanhua Ding, Chief Physician
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male/female, 18-75 years inclusive.
- Histologically-confirmed unresectable advanced tumors (breast cancer, HNSCC, cutaneous melanoma, prostate cancer, HCC, etc.);
- no effective standard therapy or disease relapse/metastasis post-standard-of-care.
- ECOG PS 0-1;
- expected survival ≥3 months.
- At least 1 measurable lesion by RECIST 1.1. Lesion in prior radiation field must have confirmed progression ≥4 weeks post-radiation. Prostate cancer subjects must meet PCWG3 progression criteria.
- At least one lesion suitable for repeated intratumoral injection.
- Adequate hematopoietic and organ function:
- Males and females of child-bearing potential agree effective contraception from ICF signature to 3 months after last dose.
- Voluntarily sign ICF and comply with study procedures.
Exclusion Criteria:
-
Past/current medical conditions
- CNS or leptomeningeal metastasis.
- Residual toxicity from prior anti-tumor therapy >Grade 1 (CTCAE 6.0), except alopecia and Grade 2 peripheral neuropathy without safety risk.
- Poorly controlled pleural / ascitic / pericardial effusion requiring local intervention or repeated drainage.
- Active autoimmune disease or high-risk history of recurrence; organ transplant with immunosuppression.
- Interstitial lung disease / non-infectious pneumonitis; pulmonary embolism within prior 12 weeks.
- Severe cardio-cerebrovascular events within 6 months; QTcF ≥470 msec; LVEF ≤50%; NYHA ≥III heart failure; history of long-QT syndrome or ongoing QTc-prolonging drugs.
- Uncontrolled hypertension (SBP>160 mmHg and/or DBP>100 mmHg) or other uncontrolled systemic diseases.
- High bleeding risk / coagulation disorders: inherited/acquired bleeding-thrombotic predisposition; major bleeding within 3 months; thrombolytics within 10 days; ongoing anticoagulant/antiplatelet therapy (except heparin for CVC patency).
- Immunodeficiency; history of solid-organ or hematopoietic stem-cell transplantation.
- Active TB within past 5 years.
- Severe infection / trauma / GI perforation / fistula / tumor vascular invasion / bowel obstruction within 4 weeks; active infection or antibiotic use within prior 2 weeks (prophylaxis allowed); unexplained fever >38.5 ℃ (tumor-related fever may be allowed per Investigator judgment).
- Other active malignancy within 3 years, except: cervical carcinoma in-situ, local basal-cell carcinoma, or malignancies cured ≥5 years without recurrence.
-
Prior medications & treatments
- Local radiotherapy completed <1 week before first dose; >30% bone-marrow / extensive-field radiotherapy completed <4 weeks before first dose.
- Anti-tumor therapy within 4 weeks or less than 5 half-lives (whichever shorter).
- Systemic corticosteroids (>10 mg prednisone equivalent/day) or other immunosuppressants within 14 days.
- Prior immunotherapy with irAEs ≥Grade 3.
- Prior systemic TLR-agonist treatment (topical TLR agonists e.g. imiquimod permitted).
- Vaccination within 1 month prior to enrolment.
-
Allergy, general status & others
- Severe hypersensitivity (CTCAE 6.0 ≥Grade 3) to any investigational product component.
- Active HBV / HCV, positive syphilis or HIV serology.
- Participated in another interventional clinical trial within 4 weeks.
- Major surgery within 4 weeks before screening or planned major surgery during study.
- Alcohol / illicit-drug / substance abuse within 12 months.
- Documented neurological/psychiatric disorders leading to poor compliance.
- Pregnant or lactating females.
- Subjects judged unsuitable by the Investigator for any other reason.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: HP007
Participate will recepit HP007 monotherpy with 4 dose groups |
Participate will recepit HP007 monotherpy with 4 dose groups |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
DLT
Tidsramme: up to one year
|
Safety endpoints: incidence and severity of DLT |
up to one year
|
|
AE
Tidsramme: up to two years
|
Safety endpoints: incidence and severity of adverse events (AE); Abnormal changes in laboratory and other tests with clinical significance |
up to two years
|
|
SAE
Tidsramme: up to two years
|
Safety endpoints: incidence and severity of serious adverse events (SAE); Abnormal changes in laboratory and other tests with clinical significance |
up to two years
|
|
MTD
Tidsramme: up to one year
|
Maximum tolerated dose (MTD) |
up to one year
|
|
RP2D
Tidsramme: up to one year
|
Recommended dose for phase II trial |
up to one year
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
ORR
Tidsramme: up to two years
|
Efficacy endpoints: Objective response rate (ORR) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
DOR
Tidsramme: up to two years
|
Efficacy endpoints: Duration of response (DOR) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
DCR
Tidsramme: up to two years
|
Efficacy endpoints: Disease control rate (DCR) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
PFS
Tidsramme: up to two years
|
Efficacy endpoints: Progression-free survival (PFS) per RECIST v1.1 or mRecist 1.1 or PCWG3 |
up to two years
|
|
OS
Tidsramme: up to two years
|
Efficacy endpoints: Overall survival (OS) |
up to two years
|
|
Peak concentration(Cmax)
Tidsramme: up to two years
|
The pharmacokinetic parameters of WJ47156:peak concentration (Cmax) |
up to two years
|
|
the time to receive Cmax(Tmax)
Tidsramme: up to two years
|
The pharmacokinetic parameters of HP007:the time to receive Cmax (Tmax) |
up to two years
|
|
Area Under the plasma concentration-time curve (AUC0-t, AUC0-∞)
Tidsramme: up to two years
|
The pharmacokinetic parameters of HP007 :area under the plasma concentration-time curve (AUC0-t, AUC0-∞) |
up to two years
|
|
Volume of distribution (Vd)
Tidsramme: up to two years
|
The pharmacokinetic parameters of HP007 :Volume of distribution (Vd) |
up to two years
|
|
Rate of clearance (C)
Tidsramme: up to two years
|
The pharmacokinetic parameters of HP007 :Rate of clearance (CL) |
up to two years
|
|
Terminal half-life (t1/2)
Tidsramme: up to two years
|
The pharmacokinetic parameters of WJ47156 :terminal half-life (t1/2), |
up to two years
|
|
Steady-state peak concentration(Cmax,ss)
Tidsramme: up to two years
|
The pharmacokinetic parameters of HP007 :steady-state peak concentration(Cmax,ss) for the main PK parameters for multiple dose |
up to two years
|
|
Plasma trough concentration at steady state(Cmin,ss)
Tidsramme: up to two years
|
The pharmacokinetic parameters of HP007:Plasma trough concentration at steady state(Cmin,ss) for the main PK parameters for multiple dose |
up to two years
|
|
Accumulation ratio for AUC
Tidsramme: up to two years
|
The pharmacokinetic parameters of HP007:Accumulation ratio of area-under-the-curve, defined as steady-state AUC within one dosing interval divided by Day 1 AUC (typically AUC₀-₂₄h). It characterizes overall systemic exposure accumulation over the dosing cycle, used for efficacy and total exposure assessment. |
up to two years
|
|
the time to receive Cmax at steady state(Tmax,ss)
Tidsramme: up to two years
|
The pharmacokinetic parameters of HP007 :the time to receive Cmax at steady state(Tmax,ss)for the main PK parameters for multiple dose) |
up to two years
|
|
Area Under the plasma concentration-time curve at steady state (AUC0-t, ss)
Tidsramme: up to two years
|
The pharmacokinetic parameters of HP007:area under the plasma concentration-time curve at steady state (AUC0-t, ss)for the main PK parameters for multiple dose) |
up to two years
|
|
ADA
Tidsramme: up to two years
|
The incidence and changes of anti-drug antibody (ADA) after treatment were observed |
up to two years
|
|
Nab
Tidsramme: up to two years
|
The incidence and changes of neutralizing antibody (Nab) after treatment were observed |
up to two years
|
|
Cytokines
Tidsramme: up to one year
|
The changes of serum cytokines (IFN-α, IFN-γ, IL-6, IL-10, and chemokines IFN-γ-inducible protein 10 (IP-10) and TNF-α )in peripheral blood before and after treatment were observed |
up to one year
|
|
Subtype of lymphocyte
Tidsramme: up to one year
|
Flow cytometry was used to detect the changes in lymphocyte subsets in peripheral blood before and after treatment |
up to one year
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HP007CH101
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .